A fluorescent imaging method for analyzing the biodistribution of therapeutic monoclonal antibodies that can distinguish intact antibodies from their breakdown products

References

• Evans JB, Syed BA. From the analyst's couch: Next-generation antibodies. Nature reviews. Drug Discovery 2014; 13:413–4; PMID:24722461; http://dx.doi.org/10.1038/nrd4255
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013; 57:6147–53; PMID:24080653; http://dx.doi.org/10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• Orlova A, Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50:417–25; PMID:19223403; http://dx.doi.org/10.2967/jnumed.108.057919
   PubMed Web of Science ®Google Scholar
• Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS One 2011; 6:e18198; PMID:21464917; http://dx.doi.org/10.1371/journal.pone.0018198
   PubMed Web of Science ®Google Scholar
• Yazaki PJ, Kassa T, Cheung CW, Crow DM, Sherman MA, Bading JR, Anderson AL, Colcher D, Raubitschek A. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 2008; 35:151–8; PMID:18312824; http://dx.doi.org/10.1016/j.nucmedbio.2007.10.010
   PubMed Web of Science ®Google Scholar
• Phenix CP, Rempel BP, Colobong K, Doudet DJ, Adam MJ, Clarke LA, Withers SG. Imaging of enzyme replacement therapy using PET. Proc Natl Acad Sci USA 2010; 107:10842–7; PMID:20534487; http://dx.doi.org/10.1073/pnas.1003247107
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009; 348:36–41; PMID:19567252; http://dx.doi.org/10.1016/j.jim.2009.06.009
   PubMed Web of Science ®Google Scholar
• Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B 2010; 98:77–94; PMID:20031443; http://dx.doi.org/10.1016/j.jphotobiol.2009.11.007
   PubMed Web of Science ®Google Scholar
• Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm 2009; 6:386–95; PMID:19718793; http://dx.doi.org/10.1021/mp800115t
   PubMed Web of Science ®Google Scholar
• Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 2009; 69:1268–72; PMID:19176373; http://dx.doi.org/10.1158/0008-5472.CAN-08-3116
   PubMed Web of Science ®Google Scholar
• Wang Y, Botvinick EL, Zhao Y, Berns MW, Usami S, Tsien RY, Chien S. Visualizing the mechanical activation of Src. Nature 2005; 434:1040–5; PMID:15846350; http://dx.doi.org/10.1038/nature03469
   PubMed Web of Science ®Google Scholar
• Miyawaki A, Llopis J, Heim R, McCaffery JM, Adams JA, Ikura M, Tsien RY. Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin. Nature 1997; 388:882–7; PMID:9278050; http://dx.doi.org/10.1038/42264
   PubMed Web of Science ®Google Scholar
• Jares-Erijman EA, Jovin TM. FRET imaging. Nat Biotechnol 2003; 21:1387–95; PMID:14595367; http://dx.doi.org/10.1038/nbt896
   PubMed Web of Science ®Google Scholar
• Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001; 19:316–7; PMID:11283581; http://dx.doi.org/10.1038/86684
   PubMed Web of Science ®Google Scholar
• Cool SK, Breyne K, Meyer E, De Smedt SC, Sanders NN. Comparison of In Vivo Optical Systems for Bioluminescence and Fluorescence Imaging. J Fluoresc 2013; 23(5):909–20; PMID:23579930
   PubMed Web of Science ®Google Scholar
• Xu H, Rice BW. In-vivo fluorescence imaging with a multivariate curve resolution spectral unmixing technique. J Biomed Opt 2009; 14:064011; PMID:20059249; http://dx.doi.org/10.1117/1.3258838
   PubMedGoogle Scholar
• Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15:5268–82; PMID:15385631; http://dx.doi.org/10.1091/mbc.E04-07-0591
   PubMed Web of Science ®Google Scholar
• Silver PA, Way JC. Molecular systems biology in drug development. Clin Pharmacol Ther 2007; 82:586–90; PMID:17637784; http://dx.doi.org/10.1038/sj.clpt.6100293
   PubMed Web of Science ®Google Scholar
• Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Luo FR, Camuso A, McGlinchey K, Rose WC. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 2006; 5:104–13; PMID:16432168; http://dx.doi.org/10.1158/1535-7163.MCT-05-0259
   PubMed Web of Science ®Google Scholar
• Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71:2250–9; PMID:21406401; http://dx.doi.org/10.1158/0008-5472.CAN-10-2277
   PubMed Web of Science ®Google Scholar
• Niu G, Li Z, Cao Q, Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 2009; 36:1510–9; PMID:19440708; http://dx.doi.org/10.1007/s00259-009-1158-1
   PubMed Web of Science ®Google Scholar
• Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, Brechbiel MW. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010; 2:550–64; PMID:20716957; http://dx.doi.org/10.4161/mabs.2.5.13054
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443–6; PMID:10742152; http://dx.doi.org/10.1038/74704
   PubMed Web of Science ®Google Scholar
• Nahta R. Molecular mechanisms of trastuzumab-based treatment in HER2-Overexpressing breast cancer. ISRN Oncol 2012; 2012:428062; PMID:23227361
   PubMedGoogle Scholar
• Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013; 6:1; PMID:23286345; http://dx.doi.org/10.1186/1756-8722-6-1
   PubMed Web of Science ®Google Scholar
• Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs 2012; 4:637–47; PMID:22909934; http://dx.doi.org/10.4161/mabs.21697
   PubMedGoogle Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81–8; PMID:16478695; http://dx.doi.org/10.1016/S1359-6446(05)03638-X
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Rietdorf J, Pepperkok R. Spectral imaging and its applications in live cell microscopy. FEBS Lett 2003; 546:87–92; PMID:12829241; http://dx.doi.org/10.1016/S0014-5793(03)00521-0
   PubMed Web of Science ®Google Scholar